Keywords
Diabetes
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To discuss the use of semaglutide in patients with type 2 diabetes mellitus (DM2), analyzing the benefit of its therapeutic adherence. Literature review: The high incidence of type 2 diabetes mellitus (DM2) highlights the need for the development of various therapies, such as semaglutide, for the appropriate clinical management of these patients. The development of DM2 leads to metabolic dysfunction, microvascular, and macrovascular complications. In this context, the use of semaglutide (either orally or subcutaneously), an incretin mimetic compound with 94% similarity to the hormone GLP-1, is highlighted. Through clinical trials conducted by various studies, this drug has shown promising results, leading to an average decrease of 0.9% in HbA1c, an average weight loss of 4.3 kg, in addition to presenting a low risk of hypoglycemia and assisting in the management of body weight. Final considerations: Given the risks of complications associated with DM2 and its progressive population incidence, knowledge about the use of semaglutide as an alternative treatment for antihyperglycemics is extremely relevant.
References
AVOGARO A e FADINI GP. Microvascular complications in diabetes: A growing concern for cardiologists. Int J Cardiol., 2019; 291: 29-35.
de OLIVEIRA D, et al. Exercício físico e Diabetes mellitus TIPO 2. Universidade Federal de Ouro Preto (UFOP), 2011; 95-107.
FERNANDES NSM. Alterações metabólicas no diabético. Trabalho apresentado à Universidade Fernando Pessoa como requisito para obtenção do grau de Mestre em Ciências Farmacêuticas, 2013; 1-59.
FORBES JM e COOPER ME. Mechanisms of diabetic complications. Physiol Rev., 2013; 93(1): 137-88.
HANSEN BB, et al. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. J Med Econ., 2020; 23(6): 650-658.
HEILE M, et al. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. J Manag Care Spec Pharm., 2018; 24(9-a Suppl): S42-S52.
JOHANSEN P, et al. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Adv Ther., 2020; 37(5): 2427-2441.
KAKU K, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes Obes Metab., 2018; 20(5): 1202-1212.
LEITER LA, et al. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab., 2020; 22(9): 1690-1695.
MATZA LS, et al. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Qual Life Res., 2021; 30(7): 2033-2043.
MINISTÉRIO DA SAÚDE. Diabetes Melittus. Caderno de Atenção Básica nº16. Brasília, Distrito Federal (2006), 56p.
NAUCK MA e QUAST DR. Cardiovascular Safety and Benefits of Semaglutide in Patients with Type 2 Diabetes: Findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne), 2021; 12: 645566.
OVERGAARD RV, et al. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. Diabetes Obes Metab., 2019; 21(1): 43-51.
PRATLEY RE, et al. Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Ther., 2021; 12(4): 1099-1116.
RODBARD HW, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab., 2018; 103(6): 2291-2301.
SCHNEIDER D, et al. The importance of patient-reported outcomes in type 2 diabetes: insight from the PIONEER program with oral semaglutide. Am J Manag Care, 2020; 26(16 Suppl): S356-S367.
SOCIEDADE BRASILEIRA DE DIABETES. Diretrizes Sociedade Brasileira de Diabetes 2019-2020. São Paulo: Editora Clannad; 2020; 455p.
SUMITA NM e ANDRIOLO A. Importância da hemoglobina glicada no controle do diabetes mellitus e na avaliação de risco das complicações crônicas. Jornal Brasileiro de Patologia e Medicina Laboratorial, 2008; 44(3): 169-174.
TAN X, et al. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs, 2017; 26(9): 1083-1089.
YALE JF, et al. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab., 2021; 23(10): 2269-2278.
YAMADA Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol., 2020; 8(5): 377-391.
ZINMAN B, et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin with or Without Metformin in Patients with Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care, 2019; 42(12): 2262-2271.